TB Archives – Page 21 of 51 – Treatment Action Group

Appeals to legislators to prioritize tuberculosis (TB) in plans for fiscal year 2017

November 4, 2019
Chad Cipiti

TAG and other U.S.-based NGOs and civil society groups sent several appeals to legislators to prioritize tuberculosis (TB) in plans for fiscal year 2017 in line with the White House’s recently released National Action Plan for Combating Multidrug-Resistant Tuberculosis. Letters to three key House and Senate subcommittees—the Labor, Health and Human Services, Education, and Related Agencies Subcommittee, the Defense Subcommittee, and the Subcommittee on State, Foreign Operations, and Related Programs.

Protestors Demand Cepheid Halve the Price of GeneXpert TB Tests to US$5

October 31, 2019
Dorrit Walsh

The high cost of GeneXpert tests for tuberculosis (TB) leaves open a critical gap in the diagnosis of TB and fails to consider volume of sales and public investments in the development of GeneXpert.

A Lower Price for Rifapentine Is Just a Start – Communities Need More Than Discounts to Access TB Preventive Therapy

October 31, 2019
Dorrit Walsh

October 31, 2019 — Civil society and community-based organizations issued this letter welcoming the availability of lower-priced rifapentine, which is an essential medicine for preventing TB. However, while all the organizations agree that this discount is a step forward, they're…

Public Investments in TB Medicine Bedaquiline Far Exceed Those of Developer Johnson & Johnson

October 31, 2019
Dorrit Walsh

Presented at the 50th Union World Conference on Lung Health, an analysis by Treatment Action Group (TAG) finds that total public expenditures on the development of bedaquiline –– an important medicine for drug-resistant tuberculosis (DR-TB) –– far exceed those of the originator company, Johnson & Johnson.

Public Investments in TB Medicine Bedaquiline Far Exceed Those of Developer Johnson & Johnson

October 31, 2019
Dorrit Walsh

TAG presented an analysis at the 50th Union World Conference on Lung Health, which found that that total public expenditures on the development of bedaquiline, an important medicine for drug-resistant tuberculosis, far exceed those of Johnson & Johnson, the originator company.

A Lower Price for Rifapentine Is Just a Start – Communities Need More Than Discounts to Access TB Preventive Therapy

October 31, 2019
Dorrit Walsh

Civil society and community-based organizations issued this statement welcoming the availability of lower-priced rifapentine, which is an essential medicine for preventing TB.

Open Letter to Cepheid: Time to Lower the Price of Xpert Cartridges to US $5

October 21, 2019
Dorrit Walsh

Letter from Organizations and Individuals to Cepheid asking them to reduce the price of Xpert MTB/RIF and Xpert MTB/RIF Ultra cartridges to US $5, inclusive of service and maintenance.

Statement: Truly Corrective Actions on Drug Pricing Will Bring Life-Saving Benefit to Consumers in the U.S. and Globally

October 16, 2019
Dorrit Walsh

This is a joint statement from TAG and Health GAP October 16, 2019 – Although Speaker Nancy Pelosi’s bill to increase affordable access to medicines in the U.S., H.R. 3, offers halting, partial steps to reduce drug prices for some…

The Tuberculosis Diagnostics Pipeline

September 26, 2019
Chad Cipiti

July 2012 By Colleen Daniels and Coco Jervis Introduction Accurate tuberculosis (TB) diagnosis has the potential to be the cornerstone of all global TB control efforts. However, the poor accuracy of the most commonly used test, sputum smear microscopy, and…

National TB Checklist

September 24, 2019
Chad Cipiti

Access to quality diagnosis, treatment, and prevention for tuberculosis (TB) is a human right. Are the necessary tests, treatments, vaccines, services and policies available where you live or work? This new checklist from Treatment Action Group (TAG) lays out simply…